NCT02308527 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02308527
Title	Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (BEACON)
Acronym	BEACON
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	University of Birmingham
Indications	neuroblastoma
Therapies	Bevacizumab + Irinotecan + Temozolomide Temozolomide + Topotecan Bevacizumab + Temozolomide Bevacizumab + Temozolomide + Topotecan Dinutuximab beta + Temozolomide Temozolomide Dinutuximab beta + Temozolomide + Topotecan Irinotecan + Temozolomide Cyclophosphamide + Dinutuximab beta + Topotecan
Age Groups:	child \| adult
Covered Countries	NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| CHE \| BEL \| AUT

No variant requirements are available.